|
1
|
Beere HM: ‘The stress of dying’: The role
of heat shock proteins in the regulation of apoptosis. J Cell Sci.
117:2641–2651. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Edwards A, Li J, Atadja P, Bhalla K and
Haura EB: Effect of the histone deacetylase inhibitor LBH589
against epidermal growth factor receptor-dependent human lung
cancer cells. Mol Cancer Ther. 6:2515–2524. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Socinski MA, Goldman J, El-Hariry I,
Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H,
Sequist LV, et al: A multicenter phase II study of ganetespib
monotherapy in patients with genotypically defined advanced
non-small cell lung cancer. Clin Cancer Res. 19:3068–3077. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Witta SE, Gemmill RM, Hirsch FR, Coldren
CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita
M, et al: Restoring E-cadherin expression increases sensitivity to
epidermal growth factor receptor inhibitors in lung cancer cell
lines. Cancer Res. 66:944–950. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Neal JW and Sequist LV: Complex role of
histone deacetylase inhibitors in the treatment of non-small-cell
lung cancer. J Clin Oncol. 30:2280–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoang T, Campbell TC, Zhang C, Kim K,
Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling
RJ, et al: Vorinostat and bortezomib as third-line therapy in
patients with advanced non-small cell lung cancer: A wisconsin
oncology network phase II study. Invest New Drugs. 32:195–199.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Lee SS, Kim CH, Yoo YD and Lee JC: The role of MET
activation in determining the sensitivity to epidermal growth
factor receptor tyrosine kinase inhibitors. Mol Cancer Res.
7:1736–1743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rho JK, Lee IY, Choi YJ, Choi CM, Hur JY,
Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, et al: Superior
efficacy and selectivity of novel small-molecule kinase inhibitors
of T790M-mutant EGFR in preclinical models of lung cancer. Cancer
Res. 77:1200–1211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gazdar AF: Epidermal growth factor
receptor inhibition in lung cancer: The evolving role of
individualized therapy. Cancer Metastasis Rev. 29:37–48. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sadiq AA and Salgia R: MET as a possible
target for non-small-cell lung cancer. J Clin Oncol. 31:1089–1096.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mahalingam D, Swords R, Carew JS, Nawrocki
ST, Bhalla K and Giles FJ: Targeting HSP90 for cancer therapy. Br J
Cancer. 100:1523–1529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beck R, Verrax J, Gonze T, Zappone M,
Pedrosa RC, Taper H, Feron O and Calderon PB: Hsp90 cleavage by an
oxidative stress leads to its client proteins degradation and
cancer cell death. Biochem Pharmacol. 77:375–383. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pantano C, Shrivastava P, McElhinney B and
Janssen-Heininger Y: Hydrogen peroxide signaling through tumor
necrosis factor receptor 1 leads to selective activation of c-Jun
N-terminal kinase. J Biol Chem. 278:44091–44096. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen H, Xia Y, Fang D, Hawke D and Lu Z:
Caspase-10-mediated heat shock protein 90 beta cleavage promotes
UVB irradiation-induced cell apoptosis. Mol Cell Biol.
29:3657–3664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jackson SE and Chester JD: Personalised
cancer medicine. Int J Cancer. 137:262–266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chong CR and Jänne PA: The quest to
overcome resistance to EGFR-targeted therapies in cancer. Nat Med.
19:1389–1400. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wheeler DL, Dunn EF and Harari PM:
Understanding resistance to EGFR inhibitors-impact on future
treatment strategies. Nat Rev Clin Oncol. 7:493–507. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bose P, Dai Y and Grant S: Histone
deacetylase inhibitor (HDACI) mechanisms of action: Emerging
insights. Pharmacol Ther. 143:323–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakagawa T, Takeuchi S, Yamada T, Ebi H,
Sano T, Nanjo S, Ishikawa D, Sato M, Hasegawa Y, Sekido Y and Yano
S: EGFR-TKI resistance due to BIM polymorphism can be circumvented
in combination with HDAC inhibition. Cancer Res. 73:2428–2434.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Busser B, Sancey L, Josserand V, Niang C,
Khochbin S, Favrot MC, Coll JL and Hurbin A: Amphiregulin promotes
resistance to gefitinib in nonsmall cell lung cancer cells by
regulating Ku70 acetylation. Mol Ther. 18:536–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jeannot V, Busser B, Vanwonterghem L,
Michallet S, Ferroudj S, Cokol M, Coll JL, Ozturk M and Hurbin A:
Synergistic activity of vorinostat combined with gefitinib but not
with sorafenib in mutant KRAS human non-small cell lung cancers and
hepatocarcinoma. Onco Targets Ther. 9:6843–6855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Leone A, Roca MS, Ciardiello C,
Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di
Gennaro E, Bruzzese F and Budillon A: Vorinostat synergizes with
EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation
of the major mitochondrial porin VDAC1 and modulation of the
c-Myc-NRF2-KEAP1 pathway. Free Radic Biol Med. 89:287–299. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bali P, Pranpat M, Bradner J, Balasis M,
Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, et
al: Inhibition of histone deacetylase 6 acetylates and disrupts the
chaperone function of heat shock protein 90: A novel basis for
antileukemia activity of histone deacetylase inhibitors. J Biol
Chem. 280:26729–26734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Scroggins BT, Robzyk K, Wang D, Marcu MG,
Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, et al:
An acetylation site in the middle domain of Hsp90 regulates
chaperone function. Mol Cell. 25:151–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishioka C, Ikezoe T, Yang J, Takeuchi S,
Koeffler HP and Yokoyama A: M S-275, a novel histone deacetylase
inhibitor with selectivity against HDAC1, induces degradation of
FLT3 via inhibition of chaperone function of heat shock protein 90
in AML cells. Leuk Res. 32:1382–1392. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ruefli AA, Ausserlechner MJ, Bernhard D,
Sutton VR, Tainton KM, Kofler R, Smyth MJ and Johnstone RW: The
histone deacetylase inhibitor and chemotherapeutic agent
suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway
characterized by cleavage of Bid and production of reactive oxygen
species. Proc Natl Acad Sci USA. 98:10833–10838. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC,
Chung HC and Kwon HJ: Anti-tumor activity of
N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone
deacetylase inhibitor. Biochem Biophys Res Commun. 356:233–238.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko
TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, et al: A
common BIM deletion polymorphism mediates intrinsic resistance and
inferior responses to tyrosine kinase inhibitors in cancer. Nat
Med. 18:521–528. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han JY, Lee SH, Lee GK, Yun T, Lee YJ,
Hwang KH, Kim JY and Kim HT: Phase I/II study of gefitinib
(Iressa(®)) and vorinostat (IVORI) in previously treated
patients with advanced non-small cell lung cancer. Cancer Chemother
Pharmacol. 75:475–483. 2015. View Article : Google Scholar : PubMed/NCBI
|
